DNTH Earnings Date: Nov 5, 2026 (Estimated) — Dianthus Therapeutics, Inc.
NASDAQ
Updated
When is DNTH's next earnings date?
Dianthus Therapeutics, Inc. (DNTH) is expected to report earnings on Thursday, November 5, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.94 on revenue of $460,928.
How did DNTH do in its last earnings report?
In its most recent report on Aug 4, 2026 (Q2 2026), Dianthus Therapeutics, Inc. posted EPS of -$0.90 versus the -$0.85 estimate, a miss of 1.1%. Revenue was $761,000 against a $297,182 estimate. The stock's 1-day post-earnings move was +1.9%.
How much does DNTH stock move after earnings?
DNTH beat EPS estimates in 4 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 7.9% (up or down) in the day after earnings.
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-04 | Q2 2026 | -0.85 | -0.90 | +1.10% | $761,000 | ❌ Miss | +1.90% | -1.73% | -3.77% |
| 2026-05-05 | Q1 2026 | -1.12 | -0.85 | +24.11% | $463,000 | ✅ Beat | +0.20% | -4.53% | -6.77% |
| 2026-03-09 | Q4 2025 | -1.01 | -1.43 | -41.58% | $284,000 | ❌ Miss | +21.52% | +19.42% | +32.21% |
| 2025-11-05 | Q3 2025 | -0.88 | -0.97 | -10.23% | $396,000 | ❌ Miss | +8.00% | +14.79% | +31.22% |
| 2025-03-11 | Q4 2024 | -0.85 | -0.81 | +4.71% | $1.3M | ✅ Beat | -6.33% | -11.29% | -30.15% |
| 2024-11-07 | Q3 2024 | -0.61 | -0.74 | -21.31% | $2.2M | ❌ Miss | -2.81% | -14.75% | -18.86% |
| 2024-03-21 | Q4 2023 | -1.01 | -0.71 | +29.70% | $457,000 | ✅ Beat | +14.32% | +7.37% | -16.82% |
| 2022-11-03 | -4.64 | -4.32 | — | $1.2M | ✅ Beat | — | — | — |
Showing last 8 quarters.